Iradimed Q3 Profit Rises 17% on Higher Sales; Narrows FY26 Revenue Guidance

Iradimed Corp. (IRMD) reported Friday a 17% increase in third-quarter net income to $6.51 million, or $0.51 per diluted share, up from $5.60 million, or $0.43 per share, a year earlier. Revenue rose 14% to $24.20 million from $21.20 million. Shares fell 8.22% to $78.31. Adjusted net income climbed to $7.12 million, or $0.55 per share, from $6.10 million, or $0.47 per share. Infusion pump sales rose to $8.69 million from $8.33 million, while patient monitoring revenue reached $8.01 million versus $6.87 million. Cash and equivalents totaled $63.29 million as of September 30. For the fourth quarter, the MRI-compatible device maker expects revenue of $25.0 million-$26.5 million and adjusted EPS of $0.57-$0.61. Full-year 2026 revenue guidance narrowed to $91.6 million-$93.1 million from $91 million-$96 million, with adjusted EPS projected at $2.07-$2.11. The company declared a quarterly dividend of $0.20 per share, payable November 27.